Ateganosine's Phase 3 in refractory NSCLC tests whether telomere-targeting immunopriming can deliver survival benefit where checkpoint inhibitors have failed

MAIA Biotechnology is a clinical-stage company developing a targeted cancer drug for patients with advanced non-small-cell lung cancer that has stopped responding to immunotherapy and chemotherapy, and the drug is not yet approved.

Ateganosine is a telomere-targeting agent being evaluated in THIO-104 Phase 3 as a combination with checkpoint inhibitors in third-line NSCLC patients who have exhausted both immunotherapy and chemotherapy. The thesis turns on whether THIO-104 interim efficacy data — DCR, ORR, and PFS versus control — demonstrate a statistically meaningful survival signal sufficient to support regulatory discussions and early approval eligibility. The primary risks are that durability signals from the small THIO-101 Phase 2 cohort do not translate at scale, and that Iovance's lifileucel and other novel agents increasingly define standard of care in this refractory population before ateganosine reaches approval.